Singapore markets close in 2 hours 49 minutes

Swedish Orphan Biovitrum AB (publ) (SOBIS.XC)

Cboe UK - Cboe UK Real-time price. Currency in SEK
Add to watchlist
279.600.00 (0.00%)
At close: 04:14PM BST
Full screen
Previous close279.60
Bid281.80 x N/A
Ask286.60 x N/A
Day's range279.60 - 279.60
52-week range201.40 - 290.60
Avg. volume4
Market cap96.862B
Beta (5Y monthly)0.23
PE ratio (TTM)44.24
EPS (TTM)6.32
Earnings date16 Jul 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Invitation: Sobi's Q2 2024 report

    Sobi plans to publish its report for the second quarter of 2024 on 16 July 2024 at 08:00 CEST.

  • PR Newswire

    Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout

    Sobi® today announced the initiation of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SEL-212. The submission is based on the results of the DISSOLVE I and II pivotal studies. SEL-212 is an innovative biologic therapy in development for the treatment of chronic refractory gout, a debilitating condition characterised by the persistent and painful buildup of urate crystals in the joints.

  • PR Newswire

    European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A

    Sobi® today announced the European Commission has granted Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity. Children, adolescents, and adults can experience non-haemophilia factor VIII activity levels (above 40%) for a significant part of the week with once-weekly prophylaxis, reaching trough level